Table 3.

Dynamics of functional parameters

Parameter	Study treatment
	Control (n = 16)		SrRan (n = 16)		SrRan + AD3 (n = 16)
	Pre-therapy	Post-therapy	Pre-therapy	Post-therapy	Pre-therapy	Post-therapy
“Up and go” test (s, mean ± SD)	15.26 ± 3.14	15.06 ± 3.06	15.74 ± 3.45	15.69 ± 3.41	15.88 ± 3.80	13.48 ± 3.28
		P = 0.37		P = 0.49		P = 0.01
				P c = 0.35		P c = 0.07
						P SR = 0.04
Median (IQR)	16.0 (12.0–17.8)	16.0 (12.0–17.2)	16.0 (13.2–18.3)	15.2 (13.0–18.4)	17.2 (11.5–18.4)	13.2 (11.0–15.6)
Difference vs. baseline (mean ± SD)		0.20 ± 0.08		0.05 ± 0.18		2.40 ± 0.53
% Change (↓ ↑) (mean ± SD)		↓ 1.23 ± 0.48		↓ 0.002 ± 1.5		↓ 14.26 ± 2.87
Rising from a chair test (s, mean ± SD)	16.85 ± 2.31	16.81 ± 2.36	16.61 ± 2.55	16.54 ± 2.55	16.83 ± 3.12	13.86 ± 2.53
		P = 0.43		P = 0.48		P = 0.005
				P c = 0.42		P c = 0.001
						P SR = 0.006
Median (IQR)	16.3 (15.0–18.6)	16.3 (14.9–18.5)	16.6 (15.1–18.0)	16.5 (15.4–18.2)	17.3 (13.9–19.4)	13.7 (11.9–15.3)
Difference vs. baseline (mean ± SD)		0.04 ± 0.02		0.07 ± 0.10		2.97 ± 0.57
% Change (↓ ↑) (mean ± SD)		↓ 0.29 ± 0.13		↓ 0.43 ± 0.62		↓ 16.66 ± 2.97
Equilibrium test (s, mean ± SD)	6.49 ± 2.54	6.49 ± 2.45	6.68 ± 2.95	6.69 ± 2.88	6.26 ± 2.35	8.88 ± 1.50
		P = 0.46		P = 0.46		P < 0.001
				P c = 0.48		P c = 0.003
						P SR = 0.02
Median (IQR)	5.63 (4.79–8.44)	5.66 (4.51–8.51)	6.41 (4.07–9.42)	6.47 (4.22–9.21)	6.04 (4.8–7.5)	10.0 (7.0–10.0)
Difference vs. baseline (mean ± SD)		0		0.01 ± 0.06		2.62 ± 0.55
% Change (↓ ↑) (mean ± SD)		0		↑ 0.76 ± 0.82		↑ 59.39 ± 14.56

AD ₃ alfacalcidol, IQR interquartile range (25th–75th percentiles), P in relation to the parameter before therapy, P _c in relation to the parameter in the control group, P _SR in relation to the parameter in SR group after therapy, SD standard deviation, SrRan strontium ranelate